Sarepta Therapeutics (SRPT)

$16.40 -0.64 (-3.76%)
Market Cap 1.72B
Revenue (ttm) 2.20B
Net Income (ttm) -713.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 5.82
Profit Margin -32.45%
Debt to Equity Ratio 0.73
Volume 2,291,600
Avg Vol 2,719,370
Day's Range N/A - N/A
Shares Out 104.99M
Stochastic %K 33%
Beta 0.42
Analysts Sell
Price Target $20.35

Company Profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dyst...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 274 4000
Address:
215 First Street, Suite 415, Cambridge, United States
SylviaLukowski688
SylviaLukowski688 Mar. 15 at 4:44 PM
$SRPT showed up on scans, curious how it behaves today.
0 · Reply
christineee123
christineee123 Mar. 15 at 1:24 PM
$SRPT Not everything is company-specific. Look at the broader market today: geopolitics, Middle East headlines, crazy worldwide conflicts.... are dragging everything down. Blame the world then?
0 · Reply
The_Free_Trader
The_Free_Trader Mar. 15 at 12:30 PM
$SRPT Makary/Prasad/Kennedy made development way harder than it should be. Investors deserved better. Elevidys now reaching patients, payers approving faster post reset, long term data crushes expectations. Fundamentals strong at these levels.
0 · Reply
MetalFistSlip
MetalFistSlip Mar. 15 at 12:31 AM
$ATOS $CAPR $NTLA $SRPT How’s the bags Lion
2 · Reply
Thaigrlsrk
Thaigrlsrk Mar. 15 at 12:02 AM
$SRPT EOQ is two weeks away!----- As previously communicated, we plan to announce our preliminary data available from our proof-of-concept studies for DM1 and FSHD programs at the end of this quarter. Of critical importance will be the safety and PK data. We expect to have serum and muscle PK to validate preclinical dose model prediction and evaluate dose response. Preliminary PD data will be valuable to further support our models to inform Phase III trial design. We look forward to sharing these early results with you.
1 · Reply
Lion0fWallSt
Lion0fWallSt Mar. 14 at 11:31 PM
$ATOS $CAPR $NTLA $SLS $SRPT Since post all 4 are red except ATOS , Poppy will short again.
1 · Reply
MidWestInvestm2
MidWestInvestm2 Mar. 14 at 9:00 PM
$SRPT Cooper got elevidys approved by insurance, $3.2M beast of a treatment, expected denials but smooth sail! Happy kid, happy family. Signals improving access for ambulatory DMD boys.
2 · Reply
free2dream
free2dream Mar. 14 at 8:53 PM
$SRPT this family show progress of their son , absolutely amazing !
0 · Reply
free2dream
free2dream Mar. 14 at 8:52 PM
$SRPT https://youtu.be/I4TCmJGpxSE?si=IVUIWkheCwe8E8l5
0 · Reply
free2dream
free2dream Mar. 14 at 8:50 PM
$SRPT another great video showing how well this kid is doing post treatment.
0 · Reply
Latest News on SRPT
Sarepta Therapeutics, Inc. (SRPT) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 3, 2026, 5:32 PM EST - 11 days ago

Sarepta Therapeutics, Inc. (SRPT) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program

Feb 27, 2026, 9:00 AM EST - 16 days ago

Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program

Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress

Feb 26, 2026, 8:30 AM EST - 17 days ago

Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress

Sarepta CEO To Jump Ship After 'Tumultuous' Year

Feb 26, 2026, 5:52 AM EST - 17 days ago

Sarepta CEO To Jump Ship After 'Tumultuous' Year

Sarepta Therapeutics CEO Ingram to retire by year end

Feb 26, 2026, 5:05 AM EST - 17 days ago

Sarepta Therapeutics CEO Ingram to retire by year end

Sarepta Therapeutics, Inc. (SRPT) Q4 2025 Earnings Call Transcript

Feb 25, 2026, 8:27 PM EST - 17 days ago

Sarepta Therapeutics, Inc. (SRPT) Q4 2025 Earnings Call Transcript

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments

Feb 25, 2026, 4:05 PM EST - 17 days ago

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments

Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan

Feb 24, 2026, 9:07 AM EST - 19 days ago

Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan

Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 8:30 AM EST - 19 days ago

Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results

Feb 11, 2026, 8:30 AM EST - 4 weeks ago

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results

Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease

Feb 4, 2026, 8:30 AM EST - 5 weeks ago

Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease

Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy Transcript

Jan 26, 2026, 1:32 PM EST - 6 weeks ago

Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy Transcript

Sarepta Stock Rises on Positive 3-Year Study Results for Elevidys

Jan 26, 2026, 8:53 AM EST - 6 weeks ago

Sarepta Stock Rises on Positive 3-Year Study Results for Elevidys

Sarepta's Duchenne gene therapy helps maintain motor function, three-year data shows

Jan 26, 2026, 8:10 AM EST - 6 weeks ago

Sarepta's Duchenne gene therapy helps maintain motor function, three-year data shows

Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients

Jan 26, 2026, 8:00 AM EST - 6 weeks ago

Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients

Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy

Jan 23, 2026, 4:05 PM EST - 7 weeks ago

Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy

Sarepta Therapeutics: Is Elevidys A Bust?

Jan 16, 2026, 9:25 AM EST - 2 months ago

Sarepta Therapeutics: Is Elevidys A Bust?

Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 2:36 PM EST - 2 months ago

Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues

Jan 12, 2026, 11:58 AM EST - 2 months ago

Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues

Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty

Jan 12, 2026, 9:30 AM EST - 2 months ago

Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty

Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington's Disease

Jan 7, 2026, 8:30 AM EST - 2 months ago

Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington's Disease

Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 8:30 AM EST - 2 months ago

Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 31, 2025, 5:20 PM EST - 2 months ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics: Why The Newborn Screening Decision For DMD Matters More Than The Stock Move Suggests

Dec 17, 2025, 6:48 AM EST - 3 months ago

Sarepta Therapeutics: Why The Newborn Screening Decision For DMD Matters More Than The Stock Move Suggests

Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027

Dec 11, 2025, 7:00 AM EST - 3 months ago

Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027

Sarepta Secures FDA Nod For Elevidys Study To Reduce Liver Injury Risk

Nov 25, 2025, 12:07 PM EST - 3 months ago

Sarepta Secures FDA Nod For Elevidys Study To Reduce Liver Injury Risk

Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Nov 25, 2025, 8:57 AM EST - 3 months ago

Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

Nov 24, 2025, 7:30 AM EST - 3 months ago

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

ARWR

Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1

Nov 24, 2025, 7:30 AM EST - 3 months ago

Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1

Sarepta Shares Jump After FDA Approves Updated Elevidys Label

Nov 14, 2025, 5:48 PM EST - 4 months ago

Sarepta Shares Jump After FDA Approves Updated Elevidys Label

Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information

Nov 14, 2025, 2:54 PM EST - 4 months ago

Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information

US FDA adds strongest warning to Sarepta gene therapy after fatal liver injuries

Nov 14, 2025, 2:08 PM EST - 4 months ago

US FDA adds strongest warning to Sarepta gene therapy after fatal liver injuries

Sarepta Therapeutics: Why High Risk, Low Return Until Mid-To-Late 2026

Nov 4, 2025, 1:39 PM EST - 4 months ago

Sarepta Therapeutics: Why High Risk, Low Return Until Mid-To-Late 2026

Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance

Nov 4, 2025, 12:33 PM EST - 4 months ago

Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance

Sarepta Stock Dumps: Pharma Bro Martin Shkreli Still Likes It

Nov 4, 2025, 12:11 PM EST - 4 months ago

Sarepta Stock Dumps: Pharma Bro Martin Shkreli Still Likes It

Sarepta Therapeutics shares plunge after disappointing trial data

Nov 4, 2025, 9:55 AM EST - 4 months ago

Sarepta Therapeutics shares plunge after disappointing trial data

Sarepta Stock Tumbles 40%. Why the Biotech's Shares Are Sinking.

Nov 4, 2025, 6:20 AM EST - 4 months ago

Sarepta Stock Tumbles 40%. Why the Biotech's Shares Are Sinking.

Sarepta Therapeutics, Inc. (SRPT) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 5:36 AM EST - 4 months ago

Sarepta Therapeutics, Inc. (SRPT) Q3 2025 Earnings Call Transcript

Sarepta slumps as gene therapy setback adds to drug pipeline woes

Nov 4, 2025, 4:27 AM EST - 4 months ago

Sarepta slumps as gene therapy setback adds to drug pipeline woes

Sarepta's stock plummets as disappointing trial data raise questions on DMD drug's success

Nov 3, 2025, 6:26 PM EST - 4 months ago

Sarepta's stock plummets as disappointing trial data raise questions on DMD drug's success

Sarepta's Duchenne gene therapy misses main goal in study

Nov 3, 2025, 4:24 PM EST - 4 months ago

Sarepta's Duchenne gene therapy misses main goal in study

Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE

Nov 3, 2025, 4:05 PM EST - 4 months ago

Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE

Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results

Oct 27, 2025, 4:05 PM EDT - 4 months ago

Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results

Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF

Oct 23, 2025, 6:46 AM EDT - 5 months ago

Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF

BLSH DASH FLY IREN NEM OPEN QS

Sarepta Therapeutics: A Discounted Valuation Meets Breakthrough Pipeline

Oct 10, 2025, 11:49 AM EDT - 5 months ago

Sarepta Therapeutics: A Discounted Valuation Meets Breakthrough Pipeline

What's Going On Sarepta Stock On Wednesday?

Oct 8, 2025, 11:19 AM EDT - 5 months ago

What's Going On Sarepta Stock On Wednesday?

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress

Oct 3, 2025, 8:30 AM EDT - 5 months ago

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year

Sep 5, 2025, 9:00 AM EDT - 6 months ago

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year

mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 7 months ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY BNTX DHR GRAL ILMN IONS MRNA

SylviaLukowski688
SylviaLukowski688 Mar. 15 at 4:44 PM
$SRPT showed up on scans, curious how it behaves today.
0 · Reply
christineee123
christineee123 Mar. 15 at 1:24 PM
$SRPT Not everything is company-specific. Look at the broader market today: geopolitics, Middle East headlines, crazy worldwide conflicts.... are dragging everything down. Blame the world then?
0 · Reply
The_Free_Trader
The_Free_Trader Mar. 15 at 12:30 PM
$SRPT Makary/Prasad/Kennedy made development way harder than it should be. Investors deserved better. Elevidys now reaching patients, payers approving faster post reset, long term data crushes expectations. Fundamentals strong at these levels.
0 · Reply
MetalFistSlip
MetalFistSlip Mar. 15 at 12:31 AM
$ATOS $CAPR $NTLA $SRPT How’s the bags Lion
2 · Reply
Thaigrlsrk
Thaigrlsrk Mar. 15 at 12:02 AM
$SRPT EOQ is two weeks away!----- As previously communicated, we plan to announce our preliminary data available from our proof-of-concept studies for DM1 and FSHD programs at the end of this quarter. Of critical importance will be the safety and PK data. We expect to have serum and muscle PK to validate preclinical dose model prediction and evaluate dose response. Preliminary PD data will be valuable to further support our models to inform Phase III trial design. We look forward to sharing these early results with you.
1 · Reply
Lion0fWallSt
Lion0fWallSt Mar. 14 at 11:31 PM
$ATOS $CAPR $NTLA $SLS $SRPT Since post all 4 are red except ATOS , Poppy will short again.
1 · Reply
MidWestInvestm2
MidWestInvestm2 Mar. 14 at 9:00 PM
$SRPT Cooper got elevidys approved by insurance, $3.2M beast of a treatment, expected denials but smooth sail! Happy kid, happy family. Signals improving access for ambulatory DMD boys.
2 · Reply
free2dream
free2dream Mar. 14 at 8:53 PM
$SRPT this family show progress of their son , absolutely amazing !
0 · Reply
free2dream
free2dream Mar. 14 at 8:52 PM
$SRPT https://youtu.be/I4TCmJGpxSE?si=IVUIWkheCwe8E8l5
0 · Reply
free2dream
free2dream Mar. 14 at 8:50 PM
$SRPT another great video showing how well this kid is doing post treatment.
0 · Reply
free2dream
free2dream Mar. 14 at 8:49 PM
$SRPT https://youtu.be/5SVUXc-bCow?si=JeAMW2n7vkzJPCDN
0 · Reply
free2dream
free2dream Mar. 14 at 8:44 PM
$SRPT investors spent several billions of dollars to develop Elevidys , years in making and shitheads like kennedy , makary and prasad acting like government MAFIA , they should all be removed as none of them are qualified for those job positions.
1 · Reply
free2dream
free2dream Mar. 14 at 8:40 PM
$SRPT watch the clip bellow... This family's son was treated with Elevidys and he is doing great. FDA is bunch of MAFIA DICKS ignoring the science ! Just look at the biopsies of the muscle tissue of treated kids vs non treated. Sarepta is a $500 stock trading at $16 , i mean WHAT THE FUCK ?
0 · Reply
free2dream
free2dream Mar. 14 at 8:37 PM
$SRPT https://youtu.be/pvTWP2HVlA0?si=RLumcPgog1jJVqLz
0 · Reply
DragonAlgo
DragonAlgo Mar. 14 at 5:05 PM
🐉 $SRPT PUT — DragonAlgo® Signal Contract: SRPT PUT Expiry: 2026-03-20 | Strike: $17.00 | Type: PUT Option Plan (premium): Entry: $1.23 Stop: $0.88 TP1: $1.59 TP2: $2.08 TP3: $2.94 Rules-based execution profile. 🔗 https://dragonalgo.com
0 · Reply
Sejeni
Sejeni Mar. 14 at 12:52 PM
$SRPT 🤣🥳
0 · Reply
Sejeni
Sejeni Mar. 14 at 12:48 PM
$SRPT
0 · Reply
fpak
fpak Mar. 14 at 10:34 AM
$SRPT https://uk.investing.com/news/insider-trading-news/sarepta-therapeutics-director-mayo-sells-123k-in-shares-93CH-4559065
1 · Reply
camiilekzey21
camiilekzey21 Mar. 14 at 7:31 AM
$SRPT SRPT bulls aren’t here for charts, we’re here for the science. Elevidys is the real story. 🧬
0 · Reply
Strouse
Strouse Mar. 14 at 7:10 AM
$SRPT One thing about biotech bulls: they usually care more about the drug data than the noise around it. Have some faith
0 · Reply
BrannonM1
BrannonM1 Mar. 14 at 5:43 AM
$SRPT Rare disease biotech creates some of the strongest bull cases because the impact of a drug can be massive for patients.
0 · Reply
Retter7
Retter7 Mar. 14 at 12:47 AM
$SRPT Despite the market being down due to global events, Mizuho has raised its price target on SRPT while maintaining an Outperform rating. First Trust Advisors LP has also increased its position in the stock. The fundamentals remain strong, and I’m staying patient and holding my position for the long term. Strong conviction holding the line.
1 · Reply